Wolfgang Miesbach: How a ‘Non‑Bleeding’ Factor XII Shapes Thrombosis and Fibrinolysis
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”The Secret Life of FXII: How a ‘Non‑Bleeding’ Factor Shapes Thrombosis and Fibrinolysis.
In her excellent talk at the EHA‑SWG Scientific Meeting on Bleeding and Platelet Disorders, Mariantonietta Tripodo addressed a fascinating question: ‘Can dual targeting of FXII and Gas6 prevent thrombosis with no risk of bleeding?’
FXII has long been viewed as dispensable for normal hemostasis because congenital FXII deficiency does not cause a bleeding phenotype.
- New data show that FXIIa actively shapes fibrin structure and promotes fibrinolysis, influencing how stable a clot is and how quickly it is broken down.
- Gas6, in turn, acts mainly at the platelet–vessel wall interface: it amplifies platelet activation and supports platelet adhesion and aggregation via TAM receptors, adding another layer of control over thrombus formation that is partly independent of classical coagulation.
- In experimental models, lack or inhibition of FXII and Gas6 reduces thrombosis and appears to spare primary hemostasis – but it also modifies fibrinolytic activity, with hints of hyperfibrinolysis when both pathways are absent.
So, the supposed ‘silent’ FXII is revealing a much more nuanced role: not a classic bleeding factor, but a regulator of clot architecture and lysis – and, together with Gas6, a highly attractive yet complex target for safer antithrombotic strategies.
I am very curious to see how these mechanistic insights will translate into future clinical trials of FXII/Gas6‑directed therapies, especially in patients where conventional anticoagulation is limited by bleeding risk.”

Stay updated with Hemostasis Today.
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support
-
Nov 17, 2026, 23:34Ahmed Bennis: Is Aspirin Therapy Enough for VTE Prevention After Arthroplasty?
-
Nov 17, 2026, 23:33Remi Remakanth: The Role of Transfusion Medicine in HLA Antibody Testing and Transplant Desensitization